Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Metabolomics is Scopus-indexed (Q2, CiteScore 5.5), WoS SCIE. Published by Springer.
Checked against the index lists dated .
ISSN 1573-3882Verify ISSN ↗1573-3890Verify ISSN ↗
Publisher: Springer
Cost to publish: About US$3,890 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Endocrinology, Diabetes and Metabolism | 92 / 250 | 63rd | Q2 |
| Clinical Biochemistry | 50 / 124 | 60th | Q2 |
| Biochemistry | 199 / 448 | 55th | Q2 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2005–present, best quartile Q2, CiteScore 5.5.
Metabolomics is Q2 in Endocrinology, Diabetes and Metabolism (rank 92 of 250), Q2 in Clinical Biochemistry (rank 50 of 124) and Q2 in Biochemistry (rank 199 of 448), by CiteScore 2025.
Metabolomics is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 5.5, which places it in quartile Q2 at the 63rd percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.936, quartile Q2, with an H-index of 107.
The publisher lists an article processing charge of about US$3,890 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Metabolomics is published by Springer. Its print ISSN is 1573-3882 and its online ISSN is 1573-3890.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Metabolomics has an h-index of 122 and a 2-year mean of 3.51 citations per paper (OpenAlex). Its Scopus CiteScore is 5.5, quartile Q2. On 2-year citations it ranks #66 of 246 Scopus journals in Endocrinology, Diabetes and Metabolism.
Metabolomics published 176 papers in 2025; its busiest recent year was 2019 with 181. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 100 research articles (2026), authors are most often from United States (22.2%), China (12.5%) and Brazil (6.5%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 2 retracted papers are recorded (0.8 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.